SCHEMBL4904690

SCHEMBL4904690

NC(=O)n1cccc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.43
POLB P06746 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
APEX1 P27695 1/20 0.43
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
PARP1 P09874 3/20 0.38
LMNA P02545 2/20 0.35
MAP3K14 Q99558 1/20 0.35
MAPT P10636 2/20 0.34
RECQL P46063 2/20 0.34
TSHR P16473 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
BLM P54132 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4334753 0.86 TDP1 (0.46) TDP1POLBL3MBTL1APEX1HDAC4
SCHEMBL5653476 0.84 LMNA (0.43) TDP1POLBL3MBTL1APEX1PARP1
SCHEMBL28151189 0.81 PARP1 (0.37) PARP1LMNAMAP3K14BCHEACHE
SCHEMBL4379296 0.78 POLB (0.43) TDP1POLBL3MBTL1APEX1HDAC4
SCHEMBL6343183 0.76 MAPT (0.40) TDP1L3MBTL1LMNAMAPTTSHR
SCHEMBL14398922 0.75 POLB (0.41) TDP1POLBL3MBTL1APEX1HDAC4
SCHEMBL27907517 0.74 ALDH1A1 (0.43) TDP1POLBL3MBTL1APEX1HDAC8
SCHEMBL4913277 0.74 POLB (0.40) TDP1POLBL3MBTL1APEX1HDAC4
SCHEMBL28614024 0.74 POLB (0.40) TDP1POLBL3MBTL1APEX1HDAC4
SCHEMBL6794236 0.74 L3MBTL1 (0.40) TDP1POLBL3MBTL1APEX1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080233410-A1 Transition metal complex compound IDEMITSU KOSAN CO., LTD. (JP) 2008-09-25 US disclosed
US-20070141397-A1 TRANSITION METAL COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE COMPOUND IDEMITSU KOSAN CO., LTD (JP) 2007-06-21 US disclosed
CN-1312153-C Pyrrolopyrimidinone derivatives, process for their preparation and their use SK CHEMICALS CO LTD (KR) 2007-04-25 CN disclosed
WO-2005011675-A1 DERIVATIVES OF 3-HYDROXY-PYRROLE-2,4-DICARBOXYLIC ACID AND USES THEREOF AVALON PHARMACEUTICALS (US) 2005-02-10 WO disclosed
CN-1422271-A Pyrrolopyrimidinone derivatives, process for their preparation and their use SK CHEMICALS CO LTD (KR) 2003-06-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080233410-A1 Transition metal complex compound EMC2, INTS9, LEF1 TDP1 3912/4885POLB 1784/4885L3MBTL1 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.